ABUS Arbutus Biopharma Corporation - Common Stock
$5.01
株価 · 8月 19, 2026
ファンダメンタルズ（時点） 8月 12, 2026
52週レンジ
$3–$5
82% of range
アナリスト評価
BUY
8 analysts
目標株価
$6
+10% upside
P/E (TTM)
-30.1
ROE
-42.0%
純利益率
-237.9%
Arbutus Biopharma Corporation - Common Stock について Wikipediaからの企業概要
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
続きを読む
Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.
History
Tekmira, as the company was formerly called, was formed as a wholly owned subsidiary of Inex Pharmaceuticals in 2005 after that company began collapsing after its regulatory and partnering strategy failed in 2004. Tekmira was fully spun out in 2007 and Tekmira absorbed the assets of Inex, which had been founded in 1992.
Inex had been developing liposomal formulations of off-patent cancer drugs, and licensed them to Talon Pharmaceuticals in 2005; Talon was acquired by Spectrum Pharmaceuticals in 2013, and three former Inex/Tekmira products reached the market and began generating royalties for Tekmira: Marqibo (liposomal vincristine), Alocrest (liposomal vinorelbine) and Brakiva (liposomal topotecan).
Inex had also acquired licenses to intellectual property, as well as staff and manufacturing facilities, concerning RNAi technology from Lynx Therapeutics in 1998; this set of technologies became the focus for Tekmira and it initially sought to develop liposomally encapsulated RNAi drugs for a broad range of indications.
Tekmira also worked on providing liposomal delivery technology to other companies. In 2007 it signed a license agreement with Alnylam Pharmaceuticals so that Alnylam could use it to deliver its own RNAi drugs; that deal was expanded into a manufacturing agreement in 2009.
Most of those products not focused on viral diseases faltered, and Tekmira had only $6.3 million in cash when it filed suit against Alnylam in 2011 for breaching its contract and stealing trade secrets. The suit was settled in 2012, with Alnylam agreeing to pay Tekmira $65 million in termination fees, and the companies negotiated a new license agreement with lower milestones and royalties, which covers Alnylam's product patisiran.
Tekmira caught the world's attention and its stock rose dramatically during the 2013 West African Ebola virus epidemic due to its drug candidate for Ebola fever, TKM-Ebola. Tekmira was developing it under a $140 million US Department of Defense contract. While its stock was trading high in January 2015, it acquired OnCore BioPharma, a company focused on hepatitis B.
On December 19, 2014, Tekmira announced the appointment of former Bill & Melinda Gates Foundation CFO Richard Henriques to the company's board of directors. The company simultaneously announced the forthcoming departure of Ian MacLachlan as Executive Vice President and Chief Technical Officer.
Development of TKM-Ebola was terminated in mid June 2015 during a Phase II trial, for lack of efficacy.
The next month, Tekmira changed its name to Arbutus Biopharma and said that it would focus on drugs to treat hepatitis B.
In March 2017 Arbutus signed another license for its liposome delivery technology, this time with Alexion Pharmaceuticals, for delivery of an mRNA drug candidate. This license was terminated in July 2017, when Alexion discontinued preclinical programs outside its core complement franchise.
In 2019, Arbutus began a phase 1 clinical study using AB-506 to treat chronic hepatitis B. The company released preliminary data in July and stopped the trial in October after two patients developed acute hepatitis. Now AB-729 is paving the way for Arbutus, as they recently received the FDA go ahead to pursue phase 2 trials, after having their data voted best in ILC, 2021; after abandoning development of previous investigational agents. AB-836, Arbutus's next generation capsid inhibitor, has shown potential against mutants in its phase 1 trials.
In July 2019, Arbutus Biopharma announced the sale of part of its royalty interest on future global net sales of ONPATTRO, an RNA interference therapeutic currently sold by Alnylam Pharmaceuticals, to OMERS for $20 million.
COVID-19
On March 10, 2023, U.S. District Judge Mitchell Goldberg rejected a bid by Moderna to dismiss some of the patent infringement claims brought against the company by Arbutus and its partner, Genevant Sciences.
Moderna settled their lawsuit and will pay Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal.
出典: Wikipedia (英語), CC BY-SA 4.0 · Wikipediaで表示 ↗
ABUS 株価スナップショット 価格、時価総額、P/E、EPS、ROE、負債/資本、52週レンジ
株価
$5.01
時価総額
$987M
P/E (TTM)
-30.1
EPS（TTM）
$-0.17
収益（TTM）
$14M
配当利回り
—
ROE
-42.0%
負債/自己資本
—
52週レンジ
$3 – $5
ABUS 株価チャート 技術指標付きの日次 OHLCV — パン、ズーム、ビューのカスタマイズ
Configure
10年間のパフォーマンス 収益、純利益、利益率、EPSのトレンド
収益と純利益
$14M
2016-12-31
→
2025-12-31
EPS
$-0.17
2016-12-31
→
2025-12-31
フリーキャッシュフロー
$-40M
2016-12-31
→
2025-12-31
利益率
-237.9%
バリュエーション P/E、P/S、P/B、EV/EBITDA比率 — 株は割高か割安か？
指標
5年トレンド
ABUS
競合中央値
P/E (TTM)
-30.1
6.7
P/S (TTM) (株価売上高倍率（TTM）)
70.1
39.8
P/B (株価純資産倍率)
12.9
4.8
Price / FCF (株価FCF倍率)
-24.9
—
収益性 粗利益率、営業利益率、純利益率、ROE、ROA、ROIC
指標
5年トレンド
ABUS
競合中央値
Operating Margin (営業利益率)
-271.0%
—
Net Profit Margin (純利益率)
-237.9%
-220.1%
ROA
-29.6%
-35.0%
ROE
-42.0%
-43.2%
財務健全性 負債、流動性、支払能力 — バランスシートの健全性
指標
5年トレンド
ABUS
競合中央値
Current Ratio (流動比率)
15.7
9.7
Quick Ratio (クイックレシオ)
15.5
—
成長 収益、EPS、純利益の成長率：前年比、3年CAGR、5年CAGR
指標
5年トレンド
ABUS
競合中央値
Revenue YoY (収益（前年比）)
128.2%
—
Revenue CAGR 3Y (収益（3年CAGR）)
-28.8%
—
Revenue CAGR 5Y (収益（5年CAGR）)
15.3%
—
資本効率 総資産回転率、棚卸資産回転率、売掛金回転率
指標
5年トレンド
ABUS
競合中央値
ABUS アナリストコンセンサス 強気・弱気のアナリストの見解、12ヶ月の目標株価、アップサイド
買い
8 アナリスト
- 強い買い 3 37.5%
- 買い 4 50.0%
- 保有 1 12.5%
- 売り 0 0.0%
- 強い売り 0 0.0%
12ヶ月目標株価
1 アナリスト · 2026-08-17
安値
$5.53
高値
$5.53
中央値ターゲット
$5.53
+10.3%
平均値ターゲット
$5.53
+10.3%
決算履歴 EPS実績 vs 予想、サプライズ%、達成率、次回決算日
平均サプライズ
0.01%
| 期間 | EPS Actual | EPS 予想 | サプライズ |
|---|---|---|---|
| 2026年3月31日 | $-0.05 | $-0.03 | -0.02% |
| 2025年12月31日 | $-0.02 | $-0.04 | 0.02% |
| 2025年9月30日 | $-0.04 | $-0.03 | -0.01% |
| 2025年6月30日 | $0.01 | $-0.05 | 0.06% |
| 2025年3月31日 | $-0.13 | $-0.11 | -0.02% |
| 2024年12月31日 | $-0.07 | $-0.08 | 0.01% |
同業他社比較（GICSサブインダストリー） 主要メトリクスとセクターピアの比較
| ティッカー | 時価総額 | P/E | 売上高 YoY | 純利益率 | ROE | 粗利益率 |
|---|---|---|---|---|---|---|
| ABUS | $926M | -28.3 | 128.2% | -237.9% | -42.0% | — |
| XENE | $3.59B | -10.3 | — | -4612.1% | -56.9% | — |
| AUPH | $2.11B | 7.7 | 20.4% | 101.5% | 62.7% | — |
| ZYME | $1.97B | -24.4 | 38.9% | -76.6% | -26.9% | — |
| ACOG | $141M | -5.5 | — | -202.2% | -43.8% | — |
完全なファンダメンタルズ 年次別全指標 — 損益計算書、貸借対照表、キャッシュフロー
損益計算書 16
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| R&D Expense | $25M | $54M | $74M | $84M | $66M | $49M | $58M | $58M | $63M | $61M | $52M | |
| SG&A Expense | $16M | $22M | $22M | $18M | $17M | $15M | $18M | $16M | $16M | $39M | $26M | |
| Operating Expenses | $52M | $82M | $96M | $104M | $85M | $65M | $150M | $96M | $122M | $493M | $127M | |
| Operating Income | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | $-144M | $-90M | $-111M | $-492M | $-104M | |
| Interest Expense | · | · | $459.0K | $2M | $3M | $4M | $2M | $226.0K | $261.0K | $0 | $0 | |
| Interest Income | $4M | $7M | $6M | $2M | $127.0K | $741.0K | $2M | $3M | $2M | $1M | $674.0K | |
| Other Non-op | $5M | $6M | $5M | $444.0K | $-3M | $-6M | $-22M | $28M | $2M | $2M | $25M | |
| Pretax Income | · | · | · | · | · | $-64M | $-166M | $-61M | $-109M | $-489M | $-79M | |
| Income Tax | $0 | $0 | $0 | $4M | $0 | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Net Income | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| EPS (Basic) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| EPS (Diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| Shares (Basic) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| Shares (Diluted) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| EBITDA | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | · | $-90M | $-111M | $-492M | · |
貸借対照表 25
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18M | $36M | $26M | $31M | $109M | $52M | $32M | $37M | $54M | $23M | $167M | |
| Short-term Investments | $73M | $86M | $100M | $116M | $46M | $71M | $59M | $88M | $72M | $107M | $15M | |
| Receivables | $1M | $2M | $2M | $1M | $899.0K | $1M | $1M | $1M | $402.0K | $273.0K | $1M | |
| Prepaid Expense | $2M | $2M | $4M | $3M | $4M | $3M | $2M | $3M | $2M | $1M | $1M | |
| Current Assets | $94M | $127M | $132M | $151M | $161M | $128M | $94M | $129M | $129M | $133M | $184M | |
| PP&E (Net) | $32.0K | $3M | $5M | $5M | $6M | $7M | $9M | $10M | $12M | $7M | $3M | |
| PP&E (Gross) | $245.0K | $16M | $17M | $16M | $15M | $15M | $14M | $17M | $25M | $18M | $13M | |
| Accum. Depreciation | $213.0K | $13M | $12M | $11M | $9M | $8M | $6M | $7M | $13M | $11M | $10M | |
| Goodwill | · | · | · | · | · | · | $0 | $22M | $24M | $24M | $163M | |
| Intangibles | · | · | · | · | · | · | $0 | $44M | $59M | $99M | $353M | |
| Other Non-current Assets | $130.0K | $34.0K | $0 | $103.0K | $61.0K | $44.0K | $293.0K | $0 | · | · | · | |
| Total Assets | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Accounts Payable | $5M | $8M | $10M | $16M | $11M | $9M | $7M | $9M | $11M | $10M | $9M | |
| Current Liabilities | $6M | $16M | $22M | $33M | $11M | $10M | $8M | $11M | $15M | $11M | $11M | |
| Capital Leases | $199.0K | $806.0K | $1M | $2M | $2M | $3M | $3M | $0 | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $13M | $17M | $41M | $146M | |
| Total Liabilities | $18M | $34M | $38M | $59M | $35M | $35M | $33M | $28M | $55M | $73M | $165M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Common Stock | $1.42B | $1.41B | $1.35B | $1.32B | $1.29B | $986M | $899M | $879M | $876M | $867M | $834M | |
| Paid-in Capital | $83M | $82M | $81M | $72M | $65M | $61M | $55M | $48M | $43M | $37M | $30M | |
| Retained Earnings | $-1.38B | $-1.35B | $-1.28B | $-1.20B | $-1.13B | $-1.05B | $-970M | $-805M | $-738M | $-653M | $-267M | |
| AOCI | $-48M | $-48M | $-48M | $-50M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-50M | |
| Stockholders' Equity | $77M | $97M | $106M | $137M | $169M | $102M | $73M | $200M | $182M | $203M | $548M | |
| Liabilities + Equity | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Shares Outstanding | 192,531,225 | 189,963,492 | 169,867,414 | 157,455,363 | 144,987,736 | 89,678,722 | 64,780,314 | 55,518,800 | 55,060,650 | 54,841,494 | 54,570,691 |
キャッシュフロー 14
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $7M | $9M | $9M | $7M | $6M | $6M | $7M | $6M | $15M | · | · | |
| Deferred Tax | · | · | · | · | · | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Restructuring | $13M | $4M | $0 | · | $0 | $64.0K | $156.0K | $5M | $0 | · | · | |
| Operating Cash Flow | $-40M | $-65M | $-86M | $-35M | $-68M | $-51M | $-71M | $-68M | $-49M | $-58M | $-56M | |
| CapEx | $0 | $182.0K | $1M | $512.0K | $809.0K | $229.0K | $589.0K | $1M | $7M | $4M | $2M | |
| Investing Cash Flow | $16M | $23M | $51M | $-75M | $-13M | $-15M | $28M | $-4M | $28M | $-99M | $8M | |
| Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | $0 | |
| Net Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | · | |
| Stock Issued | · | · | · | · | $135M | $86M | $19M | $0 | $0 | $0 | $142M | |
| Net Stock Activity | · | · | · | · | $135M | $86M | · | · | $0 | $0 | · | |
| Financing Cash Flow | $6M | $52M | $31M | $32M | $137M | $87M | $37M | $56M | $49M | $13M | $144M | |
| Net Change in Cash | $-18M | $10M | $-4M | $-79M | $57M | $20M | $-5M | $-17M | $31M | $-143M | $95M | |
| Free Cash Flow | $-40M | $-65M | $-87M | $-36M | $-68M | $-52M | · | $-69M | $-56M | $-62M | · | |
| Levered FCF | · | · | · | · | · | $-56M | · | $-69M | $-56M | · | · |
収益性 7
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| Net Margin | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% | -922.0% | · | -959.8% | -788.9% | -25765.5% | · | |
| Pretax Margin | · | · | · | · | · | -922.0% | · | -1031.8% | -1016.2% | -32807.9% | · | |
| EBITDA Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| ROA | -29.6% | -50.6% | -42.9% | -34.7% | -44.6% | -52.5% | · | -24.5% | -32.9% | -77.8% | · | |
| ROE | -42.0% | -68.5% | -64.6% | -49.2% | -50.9% | -64.0% | · | -27.5% | -43.8% | -102.4% | · | |
| ROIC | · | · | · | · | · | -56.7% | · | -41.7% | -47.2% | -190.2% | · |
流動性と支払能力 3
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 | 13.4 | · | 11.5 | 8.8 | 12.5 | · | |
| Quick Ratio | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 | 13.1 | · | 11.2 | 8.7 | 12.4 | · | |
| Interest Coverage | · | · | -170.2 | -37.9 | -25.7 | -14.4 | · | -397.3 | -425.0 | · | · |
効率性 2
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | 7.3 | 2.9 | 11.6 | 34.7 | 9.9 | 5.5 | · | 6.5 | 31.7 | 2.3 | · |
成長率 3
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 128.2% | -66.0% | -53.5% | 255.1% | 58.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -28.8% | -17.5% | 37.9% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.3% | · | · | · | · | · | · | · | · | · | · |
バリュエーション（TTM） 10
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| Net Income TTM | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| Market Cap | $926M | $621M | $425M | $367M | $564M | $318M | · | $213M | $278M | $134M | · | |
| P/E | -28.3 | -8.6 | -5.7 | -5.1 | -4.7 | -3.5 | -2.1 | -3.2 | -3.2 | -0.3 | -3.2 | |
| P/S | 65.8 | 100.7 | 23.4 | 9.4 | 51.3 | 46.0 | · | 35.8 | 26.0 | 90.1 | · | |
| P/B | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | 1.1 | 1.5 | 0.7 | · | |
| P / Tangible Book | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | · | · | · | · | |
| P / Cash Flow | -23.4 | -9.6 | -4.9 | -10.4 | -8.4 | -6.2 | · | -3.1 | -5.7 | -2.3 | · | |
| P / FCF | -23.4 | -9.6 | -4.9 | -10.2 | -8.3 | -6.2 | · | -3.1 | -5.0 | -2.2 | · | |
| Earnings Yield | -3.5% | -11.6% | -17.6% | -19.7% | -21.3% | -28.2% | -47.5% | -31.6% | -30.9% | -295.5% | -31.0% |
損益計算書 16
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $179M | $1M | $529.0K | $11M | $2M | $2M | $1M | $2M | $2M | $2M | $5M | $5M | $7M | $6M | $6M | |
| R&D Expense | $3M | $4M | $5M | $6M | $5M | $9M | $9M | $14M | $16M | $15M | $18M | $20M | $18M | $18M | $23M | $20M | |
| SG&A Expense | $4M | $6M | $4M | $3M | $3M | $6M | $5M | $5M | $8M | $5M | $5M | $6M | $6M | $6M | $4M | $3M | |
| Operating Expenses | $7M | $10M | $6M | $9M | $9M | $27M | $16M | $23M | $23M | $21M | $23M | $26M | $23M | $24M | $29M | $24M | |
| Operating Income | $-6M | $169M | $-5M | $-9M | $1M | $-26M | $-14M | $-21M | $-22M | $-19M | $-21M | $-22M | $-18M | $-17M | $-23M | $-18M | |
| Interest Expense | · | · | · | · | · | · | · | · | $34.0K | $44.0K | · | $46.0K | $171.0K | $198.0K | $309.0K | $429.0K | |
| Interest Income | $842.0K | $815.0K | $877.0K | $952.0K | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $943.0K | $694.0K | |
| Other Non-op | $821.0K | $787.0K | $2M | $917.0K | $1M | $1M | $1M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $630.0K | $244.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | $-20M | $-17M | $-16M | · | $-18M | |
| Income Tax | $0 | $0 | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-5M | $170M | $-4M | $-8M | $3M | $-25M | $-13M | $-20M | $-20M | $-18M | $-19M | $-20M | $-17M | $-16M | $-22M | $-18M | |
| EPS (Basic) | $-0.03 | $0.88 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| EPS (Diluted) | $-0.03 | $0.87 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| Shares (Basic) | 197,470,724 | 193,768,641 | -382,437,717 | 191,778,950 | 191,551,282 | 190,707,085 | -367,055,361 | 188,997,194 | 188,041,489 | 175,625,552 | -329,259,017 | 167,512,708 | 166,063,284 | 161,643,404 | -297,234,228 | 150,995,191 | |
| Shares (Diluted) | 197,470,724 | 195,214,067 | -383,286,168 | 191,778,950 | 192,399,733 | 190,707,085 | -367,055,361 | 188,997,194 | 188,041,489 | 175,625,552 | -329,259,017 | 167,512,708 | 166,063,284 | 161,643,404 | -297,234,228 | 150,995,191 | |
| EBITDA | $-6M | $169M | · | $-9M | $1M | $-25M | · | $-21M | $-22M | $-19M | · | $-22M | $-18M | $-17M | · | $-18M |
貸借対照表 22
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $24M | $18M | $22M | $37M | $37M | $36M | $32M | $63M | $43M | $26M | $18M | $27M | $41M | $31M | $24M | |
| Short-term Investments | · | · | $73M | · | · | · | $86M | · | · | · | $100M | · | · | · | $116M | · | |
| Receivables | $369.0K | $1M | $1M | $905.0K | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $1M | $2M | |
| Prepaid Expense | $2M | $2M | $2M | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $4M | $5M | $4M | $3M | $3M | $5M | |
| Current Assets | $274M | $277M | $94M | $97M | $103M | $117M | $127M | $133M | $148M | $136M | $132M | $142M | $159M | $153M | $151M | $141M | |
| PP&E (Net) | $10.0K | $22.0K | $32.0K | $137.0K | $148.0K | $168.0K | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | |
| PP&E (Gross) | · | · | $245.0K | · | · | · | $16M | · | · | · | $17M | · | · | · | $16M | · | |
| Accum. Depreciation | $235.0K | $224.0K | $213.0K | $13M | $13M | $13M | $13M | $13M | $13M | $12M | $12M | $12M | $11M | $11M | $11M | $10M | |
| Other Non-current Assets | $132.0K | $131.0K | $130.0K | $131.0K | $0 | $34.0K | $34.0K | · | · | · | $0 | $3.0K | $11.0K | $62.0K | $103.0K | $167.0K | |
| Total Assets | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Accounts Payable | $3M | $4M | $5M | $5M | $5M | $12M | $8M | $8M | $11M | $8M | $10M | $10M | $9M | $10M | $16M | $12M | |
| Current Liabilities | $3M | $5M | $6M | $5M | $5M | $19M | $16M | $19M | $23M | $20M | $22M | $22M | $25M | $25M | $33M | $28M | |
| Capital Leases | $0 | $0 | $199.0K | $391.0K | $575.0K | $626.0K | $806.0K | $978.0K | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $15M | $17M | $18M | $20M | $20M | $38M | $34M | $34M | $38M | $36M | $38M | $39M | $42M | $47M | $59M | $58M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Common Stock | $1.45B | $1.44B | $1.42B | $1.42B | $1.42B | $1.42B | $1.41B | $1.41B | $1.40B | $1.38B | $1.35B | $1.35B | $1.34B | $1.34B | $1.32B | $1.31B | |
| Paid-in Capital | $74M | $74M | $83M | $83M | $83M | $82M | $82M | $81M | $82M | $80M | $81M | $80M | $77M | $74M | $72M | $71M | |
| Retained Earnings | $-1.22B | $-1.21B | $-1.38B | $-1.38B | $-1.37B | $-1.37B | $-1.35B | $-1.33B | $-1.31B | $-1.29B | $-1.28B | $-1.26B | $-1.24B | $-1.22B | $-1.20B | $-1.18B | |
| AOCI | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-49M | $-49M | $-50M | $-50M | $-51M | |
| Stockholders' Equity | $259M | $260M | $77M | $77M | $83M | $79M | $97M | $107M | $122M | $115M | $106M | $119M | $135M | $144M | $137M | $146M | |
| Liabilities + Equity | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Shares Outstanding | 197,634,118 | 196,947,757 | 192,531,225 | 191,953,665 | 191,641,511 | 191,481,474 | 189,963,492 | 189,438,135 | 188,739,044 | 180,192,227 | 169,867,414 | 167,695,247 | 166,922,739 | 165,132,193 | 157,455,363 | 152,711,702 |
キャッシュフロー 11
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $11.0K | $11.0K | · | $11.0K | $11.0K | $330.0K | · | $336.0K | $356.0K | $355.0K | · | $369.0K | $342.0K | $334.0K | · | $343.0K | |
| Stock-based Comp | $2M | $1M | $1M | $1M | $864.0K | $4M | $2M | $2M | $3M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | |
| Restructuring | $0 | $0 | $-12M | $98.0K | $165.0K | $12M | $95.0K | $4M | $0 | $0 | $0 | $0 | · | · | · | · | |
| Other Non-cash | · | $-179M | · | · | · | $7M | · | · | · | $-4M | · | · | · | $-13M | · | · | |
| Operating Cash Flow | $-6M | $-8M | $-5M | $-6M | $-16M | $-13M | $-10M | $-21M | $-15M | $-19M | $-17M | $-22M | $-20M | $-27M | $-17M | $-19M | |
| CapEx | · | · | $0 | $0 | $0 | $0 | $86.0K | $0 | $1.0K | $95.0K | $0 | $32.0K | $859.0K | $117.0K | $134.0K | $91.0K | |
| Investing Cash Flow | $-2M | $2M | $-1M | $-10M | $16M | $11M | $13M | $-12M | $10M | $12M | $22M | $10M | $1M | $17M | $13M | $-14M | |
| Financing Cash Flow | $3M | $12M | $2M | $844.0K | $453.0K | $3M | $1M | $2M | $24M | $24M | $4M | $2M | $5M | $20M | $11M | $9M | |
| Net Change in Cash | $-5M | $6M | $-4M | $-15M | $336.0K | $746.0K | $4M | $-31M | $20M | $17M | $9M | $-10M | $-13M | $10M | $7M | $-23M | |
| Free Cash Flow | · | · | · | · | · | $-13M | · | · | · | $-19M | · | · | · | $-27M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-28M | · | · |
収益性 7
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1456.9% | · | -1601.2% | -1250.5% | -1263.9% | · | -462.8% | -395.3% | -260.4% | · | -299.2% | |
| Net Margin | -507.2% | 94.7% | · | -1463.5% | 23.5% | -1390.4% | · | -1472.5% | -1146.9% | -1166.8% | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| EBITDA Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1438.2% | · | -1601.2% | -1250.5% | -1240.7% | · | -462.8% | -395.3% | -255.4% | · | -299.2% | |
| ROA | -2.7% | 86.1% | · | -6.5% | 1.9% | -18.4% | · | -13.2% | -11.8% | -10.5% | · | -11.1% | -8.7% | -7.6% | · | -9.5% | |
| ROE | -3.0% | 100.0% | · | -8.4% | 2.5% | -25.3% | · | -17.4% | -15.4% | -13.8% | · | -15.2% | -11.9% | -10.5% | · | -12.8% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -18.1% | -13.7% | -12.1% | · | -12.2% |
流動性と支払能力 3
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 81.4 | 54.3 | · | 18.8 | 20.5 | 6.0 | · | 7.0 | 6.6 | 6.7 | · | 6.3 | 6.5 | 6.1 | · | 5.1 | |
| Quick Ratio | 5.8 | 4.9 | · | 4.5 | 7.7 | 2.0 | · | 1.8 | 2.9 | 2.2 | · | 0.9 | 1.2 | 1.7 | · | 0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -634.8 | -440.1 | · | -468.7 | -107.5 | -87.9 | · | -41.5 |
効率性 2
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.9 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.5 | 143.6 | · | 0.4 | 7.7 | 1.1 | · | 0.7 | 0.8 | 0.6 | · | 2.3 | 2.0 | 3.4 | · | 3.4 |
バリュエーション（TTM） 10
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $191M | $192M | · | $14M | $16M | $6M | · | $9M | $13M | $18M | · | $22M | $32M | $39M | · | $36M | |
| Net Income TTM | $159M | $140M | · | $-49M | $-62M | $-82M | · | $-77M | $-75M | $-71M | · | $-71M | $-65M | $-64M | · | $-67M | |
| Market Cap | $949M | $886M | · | $871M | $592M | $668M | · | $729M | $583M | $465M | · | $340M | $384M | $500M | · | $292M | |
| P/E | 5.9 | 6.3 | · | -17.5 | -9.4 | -7.9 | · | -9.0 | -7.2 | -6.1 | · | -4.6 | -5.5 | -7.0 | · | -3.4 | |
| P/S | 5.0 | 4.6 | · | 60.6 | 38.0 | 105.1 | · | 78.8 | 46.4 | 26.5 | · | 15.5 | 12.2 | 12.7 | · | 8.1 | |
| P/B | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Tangible Book | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Cash Flow | · | -109.3 | · | · | · | -49.9 | · | · | · | -24.1 | · | · | · | -18.3 | · | · | |
| P / FCF | · | · | · | · | · | -49.9 | · | · | · | -24.0 | · | · | · | -18.2 | · | · | |
| Earnings Yield | 16.9% | 15.8% | · | -5.7% | -10.7% | -12.6% | · | -11.2% | -13.9% | -16.3% | · | -21.7% | -18.3% | -14.2% | · | -29.8% |
財務諸表 損益計算書、貸借対照表、キャッシュフロー — 年次、過去5年間
損益計算書
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 収益 | $14M | $6M | $18M | $39M | $11M |
| 営業利益率 % | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% |
| 純利益 | $-34M | $-70M | $-73M | $-69M | $-76M |
| 希薄化後EPS | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
貸借対照表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流動比率 | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 |
| クイックレシオ | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 |
キャッシュフロー
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| フリーキャッシュフロー | $-40M | $-65M | $-87M | $-36M | $-68M |
最新ニュース この会社に言及した最近の見出し
マイ指標 あなた専用のウォッチリスト — 決算詳細から選択した行
📊
あなたにとって重要なメトリクスを選択 — 上記の決算詳細の任意の行の横にある➕をクリックしてください。
選択内容は保存され、すべてのティッカーで引き継がれます。
機関投資家（13F） 191 提出者 · $496.0M合計 · 時点 2026年6月30日
四半期SECフォーム13Fでこの株式の保有を報告している機関。ロングポジションのみ。単一の提出者は、別々のオプションレッグで2回表示される場合があります。 大きな反対売買のプット/コール・レッグは、通常、マーケットメイクまたはヘッジされた在庫を反映しており、方向性への確信を示すものではありません。
機関投資家の動向 — Q2 2026 対 前四半期
| 新規ポジション | 解消済みポジション | 増加 | 減少 | 純株式数増減 |
|---|---|---|---|---|
| 41 (+15 前期比) | 22 (-8 前期比) | 55 (+10 前期比) | 44 (-8 前期比) | +14.8M |
Q1 2026と比較しました。 SECフォーム13Fの提出期限は四半期末から45日後ですが、遅延提出者向けの短いバッファーが含まれます。この期間内の四半期は、直近で完全に報告されたペアを優先するためスキップされます。
| 機関投資家 | 評価額 | 株式数 | % 追跡された13Fのうち | タイプ |
|---|---|---|---|---|
| Two Seas Capital LP | $91,658,798 | 19,095,583 | 18.48% | 株式数 |
| Whitefort Capital Management, LP | $75,812,453 | 15,794,261 | 15.28% | 株式数 |
| VANGUARD GROUP INC | $38,412,670 | 7,986,002 | 7.74% | 株式数 |
| STATE STREET CORP | $37,772,059 | 7,869,179 | 7.62% | 株式数 |
| Rubric Capital Management LP | $36,158,098 | 7,532,937 | 7.29% | 株式数 |
| VANGUARD CAPITAL MANAGEMENT LLC | $33,651,259 | 7,010,679 | 6.78% | 株式数 |
| GEODE CAPITAL MANAGEMENT, LLC | $16,983,987 | 3,537,471 | 3.42% | 株式数 |
| BlackBarn Capital Partners LP | $12,000,000 | 2,500,000 | 2.42% | 株式数 |
| Woodline Partners LP | $10,952,909 | 2,281,856 | 2.21% | 株式数 |
| GOLDMAN SACHS GROUP INC | $8,545,829 | 1,780,381 | 1.72% | 株式数 |
| Jefferies Financial Group Inc. | $8,216,026 | 1,711,672 | 1.66% | 株式数 |
| NOMURA HOLDINGS INC | $7,857,989 | 1,637,081 | 1.58% | 株式数 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $7,398,998 | 1,541,458 | 1.49% | 株式数 |
| BANK OF AMERICA CORP /DE/ | $7,169,851 | 1,493,719 | 1.45% | 株式数 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $6,869,846 | 1,431,218 | 1.38% | 株式数 |
| OSAIC HOLDINGS, INC. | $6,469,756 | 1,347,866 | 1.30% | 株式数 |
| ADAR1 Capital Management, LLC | $6,087,106 | 1,268,147 | 1.23% | 株式数 |
| Deltroit Asset Management (UK) LLP | $5,760,000 | 1,200,000 | 1.16% | 株式数 |
| VANGUARD FIDUCIARY TRUST CO | $5,449,738 | 1,135,362 | 1.10% | 株式数 |
| CITIGROUP INC | $4,175,784 | 869,955 | 0.84% | 株式数 |
| BANK OF MONTREAL /CAN/ | $3,734,102 | 777,938 | 0.75% | 株式数 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $3,123,360 | 650,700 | 0.63% | 株式数 |
| MACKENZIE FINANCIAL CORP | $2,946,269 | 613,806 | 0.59% | 株式数 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $2,889,638 | 602,008 | 0.58% | 株式数 |
| Western Standard LLC | $2,605,378 | 542,787 | 0.53% | 株式数 |
| Rangeley Capital, LLC | $2,400,000 | 500,000 | 0.48% | 株式数 |
| Man Group plc | $2,272,642 | 473,467 | 0.46% | 株式数 |
| Corbin Capital Partners, L.P. | $2,231,732 | 682,487 | 0.45% | 株式数 |
| CenterBook Partners LP | $2,136,725 | 445,151 | 0.43% | 株式数 |
| Freestone Capital Holdings, LLC | $2,124,000 | 442,500 | 0.43% | 株式数 |
| CITADEL ADVISORS LLC | $1,942,541 | 404,696 | 0.39% | 株式数 |
| KENNEDY CAPITAL MANAGEMENT LLC | $1,849,430 | 385,298 | 0.37% | 株式数 |
| Swiss National Bank | $1,375,200 | 286,500 | 0.28% | 株式数 |
| Ledgewood Wealth Advisors, LLC | $1,336,493 | 278,436 | 0.27% | 株式数 |
| FMR LLC | $1,277,232 | 266,090 | 0.26% | 株式数 |
| Susquehanna Portfolio Strategies, LLC | $1,265,688 | 263,685 | 0.26% | 株式数 |
| Carrera Capital Advisors | $1,234,402 | 257,167 | 0.25% | 株式数 |
| Quinn Opportunity Partners LLC | $1,225,027 | 255,214 | 0.25% | 株式数 |
| D. E. Shaw & Co., Inc. | $1,209,614 | 252,003 | 0.24% | 株式数 |
| STATE OF WISCONSIN INVESTMENT BOARD | $1,161,682 | 242,017 | 0.23% | 株式数 |
| Campbell & CO Investment Adviser LLC | $1,106,563 | 230,534 | 0.22% | 株式数 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,080,475 | 225,099 | 0.22% | 株式数 |
| Squarepoint Ops LLC | $999,096 | 208,145 | 0.20% | 株式数 |
| MARTINGALE ASSET MANAGEMENT L P | $926,880 | 193,100 | 0.19% | 株式数 |
| RHUMBLINE ADVISERS | $909,224 | 189,423 | 0.18% | 株式数 |
| STRS OHIO | $810,720 | 168,900 | 0.16% | 株式数 |
| Bank of New York Mellon Corp | $801,067 | 166,889 | 0.16% | 株式数 |
| Caption Management, LLC | $720,000 | 150,000 | 0.15% | コールオプション |
| Caption Management, LLC | $720,000 | 150,000 | 0.15% | プットオプション |
| Hudson Bay Capital Management LP | $720,000 | 150,000 | 0.15% | 株式数 |
| Wealth Management Associates, Inc. | $710,376 | 147,995 | 0.14% | 株式数 |
| WELLINGTON MANAGEMENT GROUP LLP | $701,467 | 146,139 | 0.14% | 株式数 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $643,433 | 142,985 | 0.13% | 株式数 |
| ALLIANCEBERNSTEIN L.P. | $631,080 | 140,240 | 0.13% | 株式数 |
| Connor, Clark & Lunn Investment Management Ltd. | $619,685 | 129,101 | 0.12% | 株式数 |
| BlackRock, Inc. | $567,398 | 118,208 | 0.11% | 株式数 |
| Front Row Advisors LLC | $516,035 | 110,500 | 0.10% | 株式数 |
| BARCLAYS PLC | $499,320 | 104,025 | 0.10% | 株式数 |
| Rafferty Asset Management, LLC | $490,416 | 102,170 | 0.10% | 株式数 |
| MetLife Investment Management, LLC | $452,885 | 94,351 | 0.09% | 株式数 |
| VANGUARD ASSET MANAGEMENT, Ltd | $429,994 | 89,582 | 0.09% | 株式数 |
| TWO SIGMA INVESTMENTS, LP | $407,933 | 84,986 | 0.08% | 株式数 |
| JBF Capital, Inc. | $385,349 | 80,281 | 0.08% | 株式数 |
| Integrated Quantitative Investments LLC | $383,698 | 79,937 | 0.08% | 株式数 |
| Virtus Investment Advisers, LLC | $368,674 | 76,807 | 0.07% | 株式数 |
| XTX Topco Ltd | $365,808 | 76,210 | 0.07% | 株式数 |
| AMERICAN CENTURY COMPANIES INC | $317,832 | 66,215 | 0.06% | 株式数 |
| Invesco Ltd. | $305,616 | 63,670 | 0.06% | 株式数 |
| Rockefeller Capital Management L.P. | $302,400 | 63,000 | 0.06% | 株式数 |
| Creative Planning | $298,133 | 62,111 | 0.06% | 株式数 |
| JANUS HENDERSON GROUP PLC | $273,746 | 60,900 | 0.06% | 株式数 |
| Quantinno Capital Management LP | $273,413 | 56,961 | 0.06% | 株式数 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $265,118 | 55,233 | 0.05% | 株式数 |
| Vanguard Global Advisers, LLC | $264,730 | 55,152 | 0.05% | 株式数 |
| Mitsubishi UFJ Asset Management Co., Ltd. | $255,936 | 53,320 | 0.05% | 株式数 |
| Jump Financial, LLC | $255,178 | 53,162 | 0.05% | 株式数 |
| PROFUND ADVISORS LLC | $254,482 | 53,017 | 0.05% | 株式数 |
| WOLVERINE TRADING, LLC | $248,868 | 55,800 | 0.05% | コールオプション |
| Police & Firemen's Retirement System of New Jersey | $248,203 | 51,709 | 0.05% | 株式数 |
| Exome Asset Management LLC | $240,797 | 50,166 | 0.05% | 株式数 |
| Magnetar Financial LLC | $225,922 | 47,067 | 0.05% | 株式数 |
| State of New Jersey Common Pension Fund D | $221,602 | 46,167 | 0.04% | 株式数 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $212,664 | 44,305 | 0.04% | 株式数 |
| ALLSTATE CORP | $212,285 | 44,226 | 0.04% | 株式数 |
| Quadrature Capital Ltd | $201,619 | 42,004 | 0.04% | 株式数 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $189,475 | 39,474 | 0.04% | 株式数 |
| ARIZONA STATE RETIREMENT SYSTEM | $189,110 | 39,398 | 0.04% | 株式数 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $175,680 | 36,600 | 0.04% | コールオプション |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $171,936 | 35,820 | 0.03% | 株式数 |
| NEW YORK STATE COMMON RETIREMENT FUND | $169,286 | 35,268 | 0.03% | 株式数 |
| INTECH INVESTMENT MANAGEMENT LLC | $167,208 | 34,835 | 0.03% | 株式数 |
| Mitsubishi UFJ Trust & Banking Corp | $152,102 | 31,688 | 0.03% | 株式数 |
| VOYA INVESTMENT MANAGEMENT LLC | $151,070 | 31,473 | 0.03% | 株式数 |
| China Universal Asset Management Co., Ltd. | $150,902 | 31,438 | 0.03% | 株式数 |
| Vanguard Investments Australia, Ltd. | $150,182 | 31,288 | 0.03% | 株式数 |
| KLP KAPITALFORVALTNING AS | $148,320 | 30,900 | 0.03% | 株式数 |
| Premier Path Wealth Partners, LLC | $144,000 | 30,000 | 0.03% | 株式数 |
| BNP PARIBAS FINANCIAL MARKETS | $139,675 | 29,099 | 0.03% | 株式数 |
| SHERBROOKE PARK ADVISERS LLC | $134,627 | 27,989 | 0.03% | 株式数 |
| EntryPoint Capital, LLC | $134,112 | 27,940 | 0.03% | 株式数 |
企業インサイダー 25 人のインサイダー · 13人の役員 · 11人の取締役
| インサイダー | 役職 | 最終アクティビティ | 保有株式数 | 12ヶ月購入 | 12ヶ月売却 | 12ヶ月純額 |
|---|---|---|---|---|---|---|
| William H. Collier | President and CEO | 2019年6月24日 A | — | 0 | 0 | $0 |
| Mark J. Murray | President and CEO | 2019年3月1日 A | 341,396 | 0 | 0 | $0 |
| David C Hastings | Chief Financial Officer | 2019年3月1日 A | — | 0 | 0 | $0 |
| Bruce Cousins | EVP & Chief Financial Officer | 2017年3月24日 A | — | 0 | 0 | $0 |
| Gaston Picchio | Chief Development Officer | 2019年3月1日 A | — | 0 | 0 | $0 |
| Elizabeth Howard | Executive VP & General Counsel | 2019年3月1日 A | — | 0 | 0 | $0 |
| Michael J. Mcelhaugh | Chief Business Officer | 2019年3月1日 A | — | 0 | 0 | $0 |
| Michael J. Sofia | Chief Scientific Officer | 2019年3月1日 A | 1,503,403 | 0 | 0 | $0 |
| Koert Vandenenden | Chief Accounting Officer | 2018年12月11日 A | — | 0 | 0 | $0 |
| William T. Symonds | Chief Development Officer | 2018年4月16日 A | — | 0 | 0 | $0 |
| Peter Lutwyche | Chief Technology Officer | 2017年3月24日 A | — | 0 | 0 | $0 |
| Michael J. Abrams | Managing Director | 2016年8月16日 M | 42,097 | 0 | 0 | $0 |
| Mark Kowalski | Sr VP & Chief Medical Officer | 2016年3月15日 A | — | 0 | 0 | $0 |
| Roger Sawhney | 取締役 | 2026年6月8日 A | — | 0 | 0 | $0 |
| Robert A Beardsley | 取締役 | 2026年6月8日 A | — | 0 | 0 | $0 |
| Frank Torti | 取締役 | 2018年11月26日 A | — | 0 | 0 | $0 |
| Vivek Ramaswamy | 取締役 | 2018年6月19日 A | — | 0 | 0 | $0 |
| Keith S Manchester | 取締役 | 2018年6月19日 A | — | 0 | 0 | $0 |
| Daniel D Burgess | 取締役 | 2018年6月19日 A | — | 0 | 0 | $0 |
| Herbert J Conrad | 取締役 | 2018年6月19日 A | — | 0 | 0 | $0 |
| Richard C Henriques JR | 取締役 | 2018年6月19日 A | 1,000 | 0 | 0 | $0 |
| Frank Karbe | 取締役 | 2017年6月21日 A | — | 0 | 0 | $0 |
| Roivant Sciences Ltd. | 10%オーナー | 2021年10月18日 C | 38,847,462 | 0 | 0 | $0 |
| Andrew Lo | 10%オーナー | 2018年1月12日 P | — | 0 | 0 | $0 |
| Patrick Machado | 10%オーナー | 2018年1月12日 P | — | 0 | 0 | $0 |
SECフォーム3/4/5提出書類からのインサイダー；純額＝公開市場のP/Sのみ
アクティビストおよび5%超のオーナー 8保有
SECスケジュール13Dを提出した投資家 — 発行体の影響を与える意図（アクティビストの保有、取締役会キャンペーン、M&A）を持つ5%超の受益権所有。各行は、その提出者のポジションの最新の既知の状態を示します。
| 提出者 | 提出済み | 保有 | ステータス | 目的 | 提出書類 |
|---|---|---|---|---|---|
| Whitefort Capital Master Fund, LP, Whitefort Capital GP, LLC, Whitefort Capital Management, LP, Whitefort Capital Management GP, LLC, David Salanic, Joseph Kaplan ×5 提出書類 | 2026年4月28日 | 8.00% | 修正 | — | SEC |
| Roivant Sciences Ltd. ×14 提出書類 | 2025年2月25日 | 20.50% | 修正 | — | SEC |
| Patrick Machado ×4 提出書類 | 2019年7月17日 | — | 初回提出 | — | SEC |
| Dr. Andrew Lo ×5 提出書類 | 2019年7月17日 | — | 初回提出 | — | SEC |
| QVT Financial LP, QVT Financial GP LLC, QVT Family Office Fund LP, QVT Associates GP LLC ×6 提出書類 | 2019年7月12日 | — | 初回提出 | — | SEC |
| SVF Investments (UK) Limited, SVF Holdings (UK) LLP, SoftBank Vision Fund L.P., SVF GP (Jersey) Limited ×4 提出書類 | 2019年7月12日 | — | 初回提出 | — | SEC |
| Dexxon Holdings Ltd., Dexcel Pharma Technologies Ltd., Dan Oren ×6 提出書類 | 2019年7月12日 | — | 初回提出 | — | SEC |
| Viking Global Investors LP, Viking Global Performance LLC, Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Global Equities Master Ltd., Viking Long Fund GP LLC, Viking Long Fund Master Ltd., Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott, Rose S. Shabet ×7 提出書類 | 2019年7月12日 | — | 初回提出 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF保有状況 34のETFが保有
ウェイトは直接株式保有（N-PORT）のみを反映しています。レバレッジ型またはデリバティブベースのファンドは、表示されていない追加のスワップエクスポージャーを保有している可能性があります。
| ファンド | ウェイト | 単位 | 時点 | ソース |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0.66% | 58,600 NS | 2026年4月30日 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.50% | 24,523 SH | 2026年8月8日 | 日次 |
| IWC · iShares Trust | 0.17% | 546,359 SH | 2026年8月8日 | 日次 |
| LABU · Direxion Shares ETF Trust | 0.11% | 132,235 NS | 2026年4月30日 | N-PORT |
| SMMV · iShares Trust | 0.10% | 62,236 SH | 2026年8月8日 | 日次 |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.06% | 10,748 SH | 2026年8月8日 | 日次 |
| IBB · iShares Trust | 0.06% | 1,164,301 SH | 2026年8月8日 | 日次 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.05% | 172,487 SH | 2026年8月8日 | 日次 |
| IWO · iShares Trust | 0.04% | 1,441,824 SH | 2026年8月8日 | 日次 |
| BIB · ProShares Trust | 0.04% | 7,110 NS | 2026年5月31日 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.03% | 64,366 NS | 2026年5月31日 | N-PORT |
| IWM · iShares Trust | 0.02% | 4,026,921 SH | 2026年8月8日 | 日次 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.02% | 925,044 SH | 2026年8月8日 | 日次 |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.02% | 122,366 SH | 2026年8月8日 | 日次 |
| RSSL · Global X Funds | 0.02% | 65,520 NS | 2026年4月30日 | N-PORT |
| ITWO · ProShares Trust | 0.02% | 7,126 NS | 2026年5月31日 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0.01% | 734,401 NS | 2026年5月31日 | N-PORT |
| ISCG · iShares Trust | 0.01% | 24,628 SH | 2026年8月8日 | 日次 |
| ISCB · iShares Trust | 0.01% | 6,673 SH | 2026年8月8日 | 日次 |
| UWM · ProShares Trust | 0.01% | 5,554 NS | 2026年5月31日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 1,810,587 SH | 2026年8月8日 | 日次 |
| VHT · VANGUARD WORLD FUND | 0.01% | 430,244 SH | 2026年8月8日 | 日次 |
| FHLC · FIDELITY COVINGTON TRUST | 0.01% | 64,437 NS | 2026年4月30日 | N-PORT |
| ISCV · iShares Trust | 0.01% | 13,314 SH | 2026年8月8日 | 日次 |
| WSML · iShares Trust | 0.01% | 11,503 SH | 2026年8月8日 | 日次 |
| URTY · ProShares Trust | 0.01% | 5,639 NS | 2026年5月31日 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.00% | 5,309 NS | 2026年5月31日 | N-PORT |
| HDG · ProShares Trust | 0.00% | 141 NS | 2026年5月31日 | N-PORT |
| ITOT · iShares Trust | 0.00% | 266,009 SH | 2026年8月8日 | 日次 |
| IWV · iShares Trust | 0.00% | 49,253 SH | 2026年8月8日 | 日次 |
| SCHB · SCHWAB STRATEGIC TRUST | 0.00% | 86,163 NS | 2026年5月31日 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0.00% | 4,760 NS | 2026年5月31日 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 5,034,547 SH | 2026年8月8日 | 日次 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 13,683 SH | 2026年8月8日 | 日次 |